Harnessing the immune system against cancer by targeting CD25 | Cancer Research UK

The shared CD25 activation mechanism on regulatory and effector T-cells has been a big challenge when designing immunotherapy drugs. Cancer Research UK scientists from University College London in collaboration with Roche, have developed a new antibody that can target CD25 specifically on regulatory T-cells while leaving effector T-cells intact. Watch this antibody in action in this short animation.

Read Prof Quezada's latest Nature paper on this area of research: https://www.nature.com/articles/s43018-020-00133-0

For more information about our latest science and innovation news on:
Twitter: https://twitter.com/CRUKresearch

LinkedIn: https://www.linkedin.com/showcase/cancer-research-uk-translation-&-commercialisation-

Видео Harnessing the immune system against cancer by targeting CD25 | Cancer Research UK канала Cancer Research UK